Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546154 | 0.79 | HSP90AA1 (0.36) | — | |
| SCHEMBL13175227 | 0.78 | — | — | |
| SCHEMBL10664892 | 0.78 | ACHE (0.37) | — | |
| SCHEMBL2111129 | 0.76 | — | — | |
| SCHEMBL22889921 | 0.76 | CA2 (0.33) | CA2CA4 | |
| SCHEMBL192671 | 0.72 | CA2 (0.33) | CA2CA4 | |
| SCHEMBL3803799 | 0.69 | KDM4E (0.38) | CA2 | |
| SCHEMBL11116745 | 0.69 | HSP90AA1 (0.32) | — | |
| SCHEMBL9942466 | 0.67 | — | — | |
| SCHEMBL14507727 | 0.66 | CA2 (0.61) | CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| WO-2010117425-A1 | CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | BIOGEN IDEC MA INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | CA2 4811/4885CA4 4874/4885 |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | CA2 4209/4885CA4 4249/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | CA2 4811/4885CA4 4874/4885 |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | CA2 4209/4885CA4 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.